TABLE 2.
Placebo-corrected change-from-baseline QTcFa
| Time point (h) | ΔΔQTcF (ms) forb: |
||
|---|---|---|---|
| Gepotidacin 1,000 mg i.v. | Gepotidacin 1,800 mg i.v. | Moxifloxacin 400 mg (ms) | |
| 0.25 | 4.1 (2.6; 5.7) | 7.3 (5.7; 8.9) | 1.2 (−0.4; 2.8) |
| 0.5 | 7.4 (5.4; 9.5) | 12.9 (10.9; 14.9) | 6.3 (4.3; 8.3) |
| 1 | 8.4 (6.1; 10.7) | 16.9 (14.6; 19.2) | 9.8 (7.4; 12.1) |
| 1.5 | 10.4 (7.9; 12.9) | 19.4 (16.9; 21.9) | 9.8 (7.3; 12.3) |
| 2 | 12.1 (9.5; 14.8) | 22.2 (19.6; 24.9) | 10.3 (7.6; 12.9) |
| 2.5 | 5.5 (3.0; 7.9) | 11.9 (9.5; 14.3) | 11.7 (9.3; 14.1) |
| 3 | 4.4 (2.4; 6.3) | 6.1 (4.2; 8.0) | 12.7 (10.7; 14.6) |
| 4 | 2.5 (0.5; 4.4) | 4.6 (2.7; 6.6) | 12.4 (10.5; 14.3) |
| 6 | 2.3 (0.3; 4.3) | 4.4 (2.5; 6.4) | 9.2 (7.2; 11.1) |
| 8 | 2.4 (0.7; 4.1) | 3.0 (1.4; 4.7) | 10.0 (8.3; 11.6) |
| 12 | −0.6 (−2.8; 1.5) | 1.3 (−0.8; 3.4) | 6.5 (4.4; 8.7) |
| 24 | 1.5 (−0.1; 3.2) | 2.2 (0.5; 3.8) | 6.0 (4.4; 7.7) |
| 48 | 2.0 (0.1; 3.9) | 2.2 (0.3; 4.0) | 1.9 (0.1; 3.7) |
a
Results from the linear mixed-effects model. Primary endpoints were used.
b
Results are least-squares means with 90% CI in parentheses.